Noticias de ALT_US
Noticias del mercado
Últimas noticias sobre ALT_US — 208 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
Altimmune (ALT) Down -2.53% — Is the Sell-Off Overdone? 2026-10-23 - ETH Profile
Find the latest Altimmune, Inc. (ALT) stock quote, history, news and other vital information to help you with your stock trading and investing.
Clinical highlights from the IMPACT Phase 2b study of pemvidutide in MASH demonstrated improvements in liver fibrosis and inflammation with generally favorable gastrointestinal tolerability Oral presentation to feature new pre-clinical data showing substantial reduction in alcohol intake with pemvidutide GAITHERSBURG, Md., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, toda
Altimmune Stock Price Forecast. Should You Buy ALT?
Altimmune (NASDAQ:ALT) executives outlined the company’s strategy to build a liver-disease franchise around pemvidutide, a dual glucagon/GLP-1 agonist being developed for metabolic dysfunction-associated steatohepatitis, or MASH, alcohol use disorder, or AUD, and alcohol-related liver disease, or AL
Detailed price information for Altimmune Inc (ALT-Q) from The Globe and Mail including charting and trades.
Página 1 de 11